All In Biotech

Drug Trial Radar · NCT04567329

Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)

A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)

Last checked: Nov 20, 2026Latest source record: Aug 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 620 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

620

Actual

Start

Nov 18, 2020

Primary completion

Aug 30, 2021

Study completion Aug 30, 2021

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Sep 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this trial are to assess the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).

Conditions

  • Dry Eye Disease

Interventions

  • NOV03Drug

    100% perfluorohexyloctane

  • Saline SolutionDrug

    0.6% sodium chloride solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Total Corneal Fluorescein Staining Score (NEI Scale) in the Study Eye at Day 57Time frame: Assessed at Day 57
  2. Change From Baseline in Dryness Score (Visual Analogue Scale [VAS] Severity of Dryness) at Day 57Time frame: Assessed at Day 57

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Bausch Site 206

    Phoenix, Arizona

  • Bausch Site 202

    Garden Grove, California

  • Bausch Site 221

    Hemet, California

  • Bausch Site 214

    Inglewood, California

  • Bausch Site 226

    Murrieta, California

  • Bausch Site 213

    Santa Ana, California

  • Bausch site 236

    Westminster, California

  • Bausch site 225

    Grand Junction, Colorado

  • Bausch Site 211

    Delray Beach, Florida

  • Bausch Site 204

    Morrow, Georgia

  • Bausch Site 209

    Chicago, Illinois

  • Bausch site 218

    Hoffman Estates, Illinois

  • Bausch Site 230

    Overland Park, Kansas

  • Bausch Site 207

    Louisville, Kentucky

  • Bausch Site 228

    Havre de Grace, Maryland

  • Bausch Site 231

    Bloomington, Minnesota

  • Bausch Site 229

    St Louis, Missouri

  • Bausch Site 224

    St Louis, Missouri

  • Bausch Site 217

    Washington, Missouri

  • Bausch Site 208

    Rochester, New York

  • Bausch Site 210

    Asheville, North Carolina

  • Bausch site 233

    High Point, North Carolina

  • Bausch site 232

    Southern Pines, North Carolina

  • Bausch Site 201

    Cincinnati, Ohio

  • Bausch Site 216

    Cleveland, Ohio

  • Bausch Site 223

    Columbus, Ohio

  • Bausch Site 215

    Nashville, Tennessee

  • Bausch site 235

    Austin, Texas

  • Bausch Site 219

    Cedar Park, Texas

  • Bausch Site 212

    League City, Texas

  • Bausch site 234

    San Antonio, Texas

  • Bausch Site 222

    San Antonio, Texas

  • Bausch Site 203

    San Antonio, Texas

  • Bausch Site 220

    Norfolk, Virginia

  • Bausch Site 227

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.